Advanced glycation and lipoxidation end-products amplify inflammation. The role of a healthy diet;I prodotti terminali della glicazione e lipossidazione avanzata quali amplificatori dell'infiammazione. Il ruolo dell'alimentazione

Minerva Medica

Volumn 99, Issue 3, 2008, Pages 289-306

  Orlando, G ^a   Bengmark, S ^b,c  

^a SAN SALVATORE HOSPITAL   (Italy)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c NONE   (United Kingdom)

Author keywords

Chronic diseases; Diet; Glycosylation end products, advanced

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED LIPOXIDATION END PRODUCT;

ACUTE DISEASE; CHRONIC DISEASE; COMORBIDITY; DIETARY INTAKE; GENETIC DISORDER; HUMAN; INFECTION; INFLAMMATION; LIFESTYLE; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; REVIEW; TRANSPLANTATION;

CHRONIC DISEASE; DIET; FOOD HANDLING; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMMUNITY, NATURAL; LIFE STYLE; LIPID METABOLISM; METABOLIC SYNDROME X;

EID: 46449094947     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (186)

1. World Health Organization. Process for a global strategy on diet, physical activity and health. WHO Geneva 2003.
2. Bengmark S. Acute and "chronic" phase response - a mother of disease. Clin Nutr 2004;23:1256-66.
3. Lin BF, Huang CC, Chiang BL, Jeng SJ. Dietary fat influences Ia antigen expression, cytokines and prostaglandin E2 production in immune cells in autoimmune-prone NZBxNZW F1 mice. Brit J Nutr 1996;75: 711-22.
4. Watanabe S, Onozaki K, Yamamoto S, Okuyama H. Regulation by dietary essential fatty acid balance of tumor necrosis factor production in mouse macrophages. J Leukoc Biol 1993;53:151-6.
5. Roszkowski K, Ko HL, Beuth J, Ohshima Y, Roszkowski W, Jeljaszewicz J et al. Intestinal microflora of BALB/c-mice and function of local immune cells. Zeitschrift für Bakteriologie und Hygien 1988;270:270-9.
6. Pulverer G, Beuth J, Roszkowski W, Burrichter H, Roszkowski K, Yassin A et al. Bacteria of human physiological microflora liberate immunomodulating peptides. Zentralbl Bakteriol 1990;272:467-76.
7. Maillard LC. Action des acids amine sur des sucres: formation des melanoides per voie methodique. C R Acad Sci 1912;154:66-8.
8. Rahbar S. An abnormal hemoglobin in red cells of diabetics. Clin Chem Acta 1968;22:296-8.
9. Rahbar S. The discovery of glycated haemoglobin. A major event in the study of nonenzymatic chemistry in biological systems. Ann N Y Acad Sci 2005;1043:9-19.
10. Chavakis T, Bierhaus A, Nawroth PP. RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microb Infect 2004;6:1219-25.
11. Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM et al. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobioiogy 2005;15:16R-28R.
12. Das UN. Metabolic syndrome X: an inflammatory condition? Current Hypertension Reports 2004;6:66-73.
13. Black PH. The inflammatory response is an integral part of stress response: implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. Brain Behav Immunol 2003,17:350-64.
14. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004;27:813-23.
15. Libby P. Inflammation in atherosclerosis. Nature 2003;420:868-74.
16. Bierhaus A, Humpert PM, Stern DM, Arnold B, Nawroth PP. Advanced glycation end product receptor-mediated cellular dysfunction. Ann N Y Acad Sci 2005;1043:676-80.
17. Schmidt AM, Yan SD, Yan SF, Stem DM. The multiligand receptor RAGE is a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;108:949-55.
18. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-ÎB. Diabetes 2001;50:2792-808.
19. Vlassara H. Advanced glycation in health and disease. Role of the modern environment. Ann N Y Acad Sci 2005;1043:452-60.
20. Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 2002;99:15596-601.
21. Peppa M, Uribarri J, Cai W, Lu M, Vlassara H. Glycoxidation and inflammation in renal failure patients. Am J Kidney Dis 2004;43:690-5.
22. Lin RY, Choudhury RP, Cai W, Lu M, Fallon JT, Fisher EA et al. Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2003;168:213-20.
23. Zheng F, He C, Cai W, Hattori M, Steffes M, Vlassara H. Prevention of nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev 2002;18:224-37.
24. Peppa M, Brem H, Ehrlich P, Zhang JG, Cai W, Li Z et al. Adverse effects of glycotoxins on wound healing in genetically diabetic mice. Diabetes 2003;52:2805-13.
25. Cai W, He JC, Lu M et al. Amelioration of insulin resistance, weight gain and markers of oxidant stressing aging mice by dietary glycotoxin restriction: a therapeutic alternative to caloric restriction. Diabetes 2004;(Suppl 2):A343.
26. Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, He C et al. Restriction of dietary glycotoxins markedly reduces AGE toxins in renal failure patients. J Am Soc Nephrol 2003;14:728-31.
27. LI SY, Sigmin VK, McCort A, Ren J. High fat diet enhances visceral advanced glycation end products, nuclear O-Glc-Nac modification, p38 mitogen-activated protein kinase activation and apoptosis. Diab Obes Metab 2005;7:448-54.
28. Hartroft WS, Thomas WA. Pathological lesions related to disturbances of fat and cholesterol metabolism in man. JAMA 1957;164:1899-905.
29. Thorpe SR, Baynes JW. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 2003;25:275-81.
30. Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in atherosclerosis. Free Radic Biol Med 2000;28:1708-16.
31. Thorpe SR, Baynes JW. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 2003;25:275-81.
32. Vamvakas S, Bahner U, Heidland A. Cancer in end-stage renal disease: potential factors involved. Am J Nephrol 1998;18:89-95.
33. Loske C, Neumann A, Cunningham AM, Nichol K, Schinzel R, Riederer P et al. Cytotoxicity of advanced glycation endproducts is mediated by oxidative stress. J Neural Transm 1998;105:1005-15.
34. Morena M, Cristol JP, Senécal L, Leray-Moragues H, Krieter D, Canaud B. Oxidative stress in hemodialysis patients: is NADPH oxidase complex the culprit? Kidney Int 2002;80(Suppl):S109-14.
35. Descamps-Latscha B, Jungers BP, Witko-Sarsat V. Immune system dysregulation in uremia: the role of oxidative stress. Blood Purif 2002;20:481-4.
36. Zevin D, Malachi T, Gafter U, Friedman J, Levi J. Impaired DNA repair in patients with end-stage renal disease and its improvement with hemodialysis. Miner Electrol Metab 1991;17:303-6.
37. Mullarkey CJ, Edelstein D, Brownlee M. Free radical generation by early glycation products; a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 1990;173:932-9.
38. Agalou S, Ahmed N, Dawnay A, Thornally PJ. Removal of advanced glycation products in clinical renal failure by peritoneal dialysis and haemodialysis. Biochem Soc Trans 2003;31:1394-6.
39. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertension 2003;21:3-12.
40. Yamagishi S, Fujimori H, Yonekura H, Yamamoto Y, Yamamoto H. Advanced glycation end products inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologica 1998;41:1435-41.
41. Suzuma I, Mandai M, Takagi H, Suzuma K, Otani A, Oh H et al. 17-Beta-estradiol increases VEGF receptor-2 and promotes DNA synthesis in retinal microvascular endothelial cells. Invest Ophthalmol Vis Sci 1999;40:2122-29.
42. Rautava S, Isolauri E. Cow's milk allergy in infants with atopic eczema is associated with aberrant production of interleukin-4 during oral cow's milk challenge. J Pediatr Gastroenterol Nutr 2004;39:529-35.
43. Artaud-Wild SM, Connor SL, Sexton G, Connor WE. Differences in coronary mortality can be explained by differences in cholesterol and saturated fat intakes in 40 countries but not in France and Finland. A paradox. Circulation 1993;88:2771-9.
44. Moss M, Freed DL. Survival trends, coronary event rates, and the MONICA project. Monitoring trends and determinants in cardiovascular disease. Lancet 1999;354:862-5.
45. Dahl-Jorgensen K, Joner G, Hanssen KF. Relationship between cows' milk consumption and incidence of IDDM in childhood. Diabetes Care 1991;14:1081-3.
46. Gimeno SG, de Souza JM. IDDM and milk consumption. A case-control study in Sao Paulo. Brazil Diabetes Care 1997;20:1256-60.
47. Virtanen SM, Hyppönen E, Läärä E, Vähäsalo P, Kulmala P, Savola K et al. Cow's milk consumption, disease-associated autoantibodies and type 1 diabetes mellitus: a follow-up study in siblings of diabetic children. Childhood Diabetes in Finland Study Group. Diabet Med 1998;15:730-8.
48. Park M, Ross GW, Petrovitch H, White LR, Masaki KH, Nelson JS et al. Consumption of milk and calcium in midlife and the future risk of Parkinson disease. Neurology 2005;64:1047-51.
49. Outwater JL, Nicholson A, Barnard N. Dairy products and breast cancer: the IGF-I, estrogen, and bGH hypothesis. Med Hypotheses 1997;48:453-61.
50. Hjartaker A, Laake P, Lund E. Childhood and adult milk consumption and risk of premenopausal breast cancer in a cohort of 48,844 women the Norwegian women and cancer study. Int J Cancer 2001;93:888-93.
51. Ganmaa D, Li XM, Wang J, et al. Incidence and mortality of testicular and prostatic cancers in relation to world dietary practices. Int J Cancer 2002;98:262-267.
52. Ganmaa D, Li XM, Wang J, Qin LQ, Wang PY, Sato A. The experience of Japan as a clue to the etiology of testicular and prostatic cancers. Med Hypotheses 2003;60:724-30.
53. Larsson SC, Bergkvist L, Wolk A. Milk and lactose intakes and ovarian cancer risk in the Swedish Mammography Cohort. Am J Clin Nutr 2004;80:1353-7.
54. Genkinger JM, Hunter DJ, Spiegelman D, Anderson KE, Arslan A, Beeson WL et al. Dairy products and ovarian cancer: a pooled analysis of 12 cohort studies. Cancer Epidemiol Biomarkers Prev 2006;15:364-72.
55. Zittermann A, Schleithoff SS, Koerfer R. Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr 2005;94:483-92.
56. McCarty MF Secondary hyperparathyroidism promotes the acute phase response - a rational for supplementing vitamin D in prevention of vascular events in elderly. Med Hypotheses 2005;64:1022-6.
57. Meerwaldt R, Links T, Graaff R, Thorpe SR, Baynes JW, Hartog J et al. Simple noninvasive measurement of skin autofluorescence. Ann N Y Acad Sci 2005;1043: 290-8.
58. Unno Y, Sakai M, Sakamoto Y, Kuniyasu A, Nakayama H, Nagai R et al. Advanced glycation end products-modified proteins and oxidized LDL mediate down-regulation of leptin in mouse adipocytes via CD36. Biochem Biophys Res Commun 2004;325:151-6.
59. Soldatos G, Cooper ME, Jandeleit-Dahm KA. Advanced-glycation end products in insulin-resistant states. Curr Hypertens Rep 2005;7:96-102.
60. Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005;25:2587-93.
61. Davis PJ, Smales CM, James DC. How can thermal processing modify the antigenicity of proteins? Allergy 2001;56(Suppl 67):56-60.
62. Sancho AI, Rigby NM, Zuidmeer L, Asero R, Mistrello G, Amato S et al. The effect of thermal processing on the IgE reactivity of the non-specific lipid transfer protein from apple, Mal d 3. Allergy 2005;60:1262-8.
63. Chung SY, Champagne ET. Association of end-product adducts with increased IgE binding of roasted peanuts. J Agric Food Chem 2001;49:3911-6.
64. Franck P, Moneret Vautrin DA, Dousset B, Kanny G, Nabet P, Guénard-Bilbaut L et al. The allergenicity of soybean-based products is modified by food technologies. Int Arch Allergy Immunol 2002;128:212-9.
65. Tsukahara H, Shibata R, Ohta N, Sato S, Hiraoka M, Ito S et al. High levels of urinary pentosidine, an advanced glycation end product, in children with acute exacerbation of atopic dermatitis: relationship with oxidative stress. Metabolism 2003;52:1601-5.
66. Nicolls MR. The clinical and biological relationship between type II diabetes mellitus and Alzheimer's disease. Curr Alzheimer Res 2004;1:47-54.
67. Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stern D et al. Advanced Maillard reaction end products are associated with Alzheimer pathology. Proc Soc Natl Acad Sci USA 1994;91:5710-4.
68. Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Soc Natl Acad Sci USA 1994;91:4766-70.
69. Moreira PI, Smith MA, Zhu X, Nunomura A, Castellani RJ, Perry G. Oxidative stress and neurodegeneration. Ann N Y Acad Sci 2005;1043:543-52.
70. Lue L-F, Yan SD, Stern DM, Walker DG. Preventing activation of receptor for advance glycation end products in Alzheimer's disease. Curr Drug Targets CNS Neurol Disord 2005;4:249-66.
71. Castellani R, Smith MA, Richey PJ, Petty G. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res 1996;737:195-200.
72. Dalfó E, Portero-Otín M, Ayala V, Martínez A, Pamplona R, Ferrer I. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol 2005;64:816-30.
73. Kikuchi S, Shinpo K, Ogata A, Tsuji S, Takeuchi M, Makita Z et al. Detection of N-(carboxymethyl)lysine (CML) and non-CML advanced glycation end products in the anterior horn of amyotrophic lateral sclerosis spinal cord. Amyotroph Lateral Scler Other Motor Neuron Disord 2002;3:63-8.
74. Chou SM, Wang HS, Taniguchi A, Bacula R. Advanced glycation end products in neurafilament conglomeration of motorneurons in familial and sporadic amyotrophic lateral sclerosis. Mol Med 1998:4:324-32.
75. Kaufmann E, Boehm BO, Süssmuth SD, Kientsch-Engel R, Sperfeld A, Ludolph AC et al. The advanced glycation end-product N epsilon-(carboxymethyl)lysine level is elevated in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Neurosci Lett 2004;371:226-9.
76. Ma L, Nicholson LF. Expression of the receptor for advanced glycation end products in Huntington's disease caudate nucleus. Brain Res 2004;1018:10-7.
77. Zimmerman GA, Meistrell M, Bloom O et al. Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci U S A 1995;92: 3744-8.
78. Gomes R, Sousa Silva M, Quintas A, Cordeiro C, Freire A, Pereira P et al. Argpyrimidine, a methylglyoxal-derived advanced glycation end-product in familial amyloidotic polyneuropathy. Biochem J 2005;385: 339-45.
79. Sasaki N, Takeuchi M, Chowei H, Kikuchi S, Hayashi Y, Nakano N et al. Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jacob disease with prion plaques. Neurosci Lett 2002;326:117-20.
80. Thiel R, Fowkes SW. Can cognitive deterioration associated with Down syndrome be reduced? Med Hypotheses 2005;64:524-32.
81. Frey J. Bovine spongiform encephalopathy: are the cows mad or full of carbohydrate. Clin Chem Lab Med 2002;40:101-3.
82. Vlassara H, Palace MR. Diabetes and advanced glycation end products. J Int Med 2002;251:87-101.
83. Hostettler-Allen RL, Tappy L, Blum JW. Insulin resistance, hyperglycemia, and glucosuria in intensively milk-fed calves. J Anim Sci 1994;72:160-73.
84. Kalousova M, Zak A, Soukupova J Advanced glycation and oxidation products in patients with atherosclerosis. Cas Lek Cesk 2005;144:385-90.
85. Taki K, Takayama F, Tsuruta Y, Niwa T. Oxidative stress, advanced glycation end product, and coronary artery calcification in hemodialysis patients. Kidney Int 2006;70:218-24.
86. Tokita Y, Hirayama Y, Sekikawa A, Kotake H, Toyota T, Miyazawa T et al. Fructose ingestion enhances atherosclerosis and deposition of advanced glycated end-products in cholesterol-fed rabbits. J Atheroscler Thromb 2005;12:260-7.
87. Ferretti G, Bacchetti T, Negre-Salvayre A Structural modifications of HDL and functional consequences. Atherosclerosis 2006;184:1-7.
88. de Leeuw K, Kallenberg C, Bijl M. Accelerated atherosclerosis in patients with systemic autoimmune diseases. Ann N Y Acad Sci 2005;1051:362-71.
89. Ge J, Jia Q, Liang C, Luo Y, Huang D, Sun A et al. Advanced glycosylation end products might promote atherosclerosis through inducing the immune maturation of dendritic cells. Arterioscler Thromb Vasc Biol 2005;25:2157-63.
90. Bartling B, Hofmann HS, Weigle B, Silber RE, Simm A. Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis 2005;26:293-301.
91. Takada M, Hirata K, Ajiki T, Suzuki Y, Kuroda Y. Expression of receptor for advanced glycation end products (RAGE) and MMP-9 in human pancreatic cancer cells. Hepatogastroenterology 2004;51:928-30.
92. Yamagishi S, Nakamura K, Inoue H, Kikuchi S, Takeuchi M. Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients. Med Hypotheses 2005;64:1208-10.
93. Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 2005;64:92-100.
94. Stitt AL. The Maillard reaction in eye disease. Ann N Y Acad Sci 2005;1043:582-97.
95. Gaby AR. Adverse effects of dietary fructose. Altern Med Rev 2005;10:294-306.
96. Wada R, Yagihashi S. Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Ann N Y Acad Sci 2005;1043:598-604.
97. Monnier VM, Sell DR, Genuth S. Glycation products as markers and predictors of the progression of diabetic complications. Ann N Y Acad Sci 2005;1043:567-81.
98. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005;11: 2279-99.
99. Hertoghe T. The "multiple hormone deficiency" theory of aging: is human senescence caused mainly by multiple hormone deficiencies? Ann N Y Acad Sci 2005;1057:448-65.
100. Diamanti-Kandarakis E, Piperi C, Kalofoutis A, Creatsas G. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol 2005;62:37-43
101. Flyvbjerg A, Khatir DS, Jensen LJ, Dagnaes-Hansen F, Gronbaek H, Rasch R. The involvement of growth hormone (GH), insulin-like growth factors (IGFs) and vascular endothelial growth factor (VEGF) in diabetic kidney disease. Curr Pharm Des 2004;10:3385-94.
102. Allen TJ, Jandeleit-Dahm KA. Preventing atherosclerosis with angiotensin-converting enzyme inhibitors: emphasis on diabetic atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:503-12.
103. Tikellis C, Cooper ME, Thomas MC. Role of the renin-angiotensin system in the endocrine pancreas: Implications for the development of diabetes. Int J Biochem Cell Biol 2005;38:737-51.
104. Ahmed N, Lüthen R, Häussinger D, Sebekova K, Schinzel R, Voelker W et al. Increased protein glycation in cirrhosis and therapeutic strategies to prevent it. Ann N Y Acad Sci 2005;1043:718-24.
105. Sebekova K, Kupcova V, Schinzel R, Heidland A. Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis - amelioration by liver transplantation. J Hepatol 2002;36:66-71.
106. Yagmur E, Tacke F, Weiss C, Lahme B, Manns MP, Kiefer P et al. Elevation of Nepsilon-(carboxymethyl)lysine-modified advanced glycation end products in chronic liver disease is an indicator of liver cirrhosis. Clin Biochem 2006;39:39-45.
107. Zeng S, Feirt N, Goldstein M, Guarrera J, Ippagunta N, Ekong U et al. Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology 2004;39:422-32 .
108. Ekong U, Zeng S, Dun H, Feirt N, Guo J, Ippagunta N et al. Blockade of the receptor for advanced glycation end products attenuates acetaminophen-induced hepatotoxicity in mice. J Gastroenterol Hepatol 2006;21:682-8 .
109. Nadeem A, Raj HG, Chhabra SK Increased oxidative stress and altered levels of antioxidants in chronic obstructive pulmonary disease. Inflammation 2005;29:23-32.
110. Hartl D, Starosta V, Maier K, Beck-Speier I, Rebhan C, Becker BF et al. Inhaled glutathione decreases PGE2 and increases lymphocytes in cystic fibrosis lungs. Free Radic Biol Med 2005;39:463-72.
111. Rahman I, Biswas SK, Kode A. Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol 2006;533:222-39.
112. DeGroot J. The AGE of the matrix: chemistry, consequence and cure. Curr Opin Pharmacol 2004;4: 301-5.
113. Steenvoorden MM, Huizinga TW, Verzijl N, Bank RA, Ronday HK, Luning HA et al. Activation of receptor for advanced glycation end products in osteoarthritis leads to increased stimulation of chondrocytes and synoviocytes. Arthritis Rheum 006;54:253-63.
114. Hormel SE, Eyre DR. Collagen in the ageing human intervertebral disc: an increase in covalently bound fluorophores and chromophores. Biochim Biophys Acta 1991;1078:243-50.
115. Reddy GK. Cross-linking in collagen by nonenzymatic glycation increases the matrix stiffness in rabbit achilles tendon. Exp Diabesity Res 2004;5:143-53.
116. Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, Lu Y et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 2002;3:117-8.
117. Hein GE, Köhler M, Oelzner P, Stein G, Franke S. The advanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis. Rheumatol Int 2005;26:137-41.
118. Sunahori K, Yamamura M, Yamana J, Takasugi K, Kawashima M, Makino H. Increased expression of receptor for advanced glycation end products by synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum 2006;54:97-104.
119. Ramamurthy B, Hook P, Jones AD, Larsson L. Changes in myosin structure and function in response to glycation. FASEB J 2001;15:2415-22.
120. Hein G, Wiegand R, Lehmann G, Stein G, Franke S. Advanced glycation end-products pentosidine and N epsilon-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology 2003;42:1242-6.
121. Odetti P, Rossi S, Monacelli F, Poggi A, Cirnigliaro M, Federici M et al. Advanced glycation end products and bone loss during aging. Ann N Y Acad Sci 2005;1043:710-7.
122. Miyata T, Kawai R, Taketomi S, Sprague SM. Possible involvement of advanced glycation end-products in bone resorption. Nephrol Dial Transplant 1996;11(Suppl 5):54-7.
123. Stamatas GN, Estanislao RB, Suero M, Rivera ZS, Li J, Khaiat A et al. Facial skin fluorescence as a marker of the skin's response to chronic environmental insults and its dependence on age. Br J Dermatol 2006;154:125-32.
124. Meerwaldt R, Hartog JW, Graaff R, Huisman RJ, Links TP, den Hollander NC et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:3687-93.
125. Hollá LI, Kanková K, Fassmann A, Bucková D, Halabala T, Znojil V et al. Distribution of the receptor for advanced glycation end products gene polymorphisms in patients with chronic periodontitis: a preliminary study. J Periodontol 2001;72:1742-6.
126. Katz J, Bhattacharyya I, Farkhondeh-Kish F, Perez FM, Caudle RM, Heft MW. Expression of the receptor of advanced glycation end products in gingival tissues of type 2 diabetes patients with chronic periodontal disease: a study utilizing immunohistochemistry and RT-PCR. J Clin Periodontol 2005;32:40-4.
127. Ostergaard J, Hansen TK, Thiel S, Flyvbjerg A. Complement activation and diabetic vascular complications. Clin Chim Acta 2005;361:10-9.
128. Bohlender JM, Franke S, Stein G, Wolf G. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 2005;289:F645-59.
129. Khan ZA, Farhangkhoee H, Chakrabarti S. Towards newer molecular targets for chronic diabetic complications. Curr Vasc Pharmacol 2006;4:45-57.
130. Thomas MC, Forbes JM, Cooper ME. Advanced glycation end products and diabetic nephropathy. Am J Ther 2005;12:562-72.
131. Kalousová M, Zima T, Tesar V, Dusilová-Sulková S, Skrha J. Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat Res 2005;579:37-46.
132. Saito A, Takeda T, Sato K, Hama H, Tanuma A, Kaseda R et al. Significance of proximal tubular metabolism of advanced glycation end products in kidney diseases. Ann N Y Acad Sci 2005;1043:637-43.
133. Jensen LJ, Ostergaard J, Flyvbjerg A. AGE-RAGE and AGE Cross-link interaction: important players in the pathogenesis of diabetic kidney disease. Horm Metab Res 2005;37(Suppl 1):26-34.
134. Agalou S, Ahmed N, Babaei-Jadidi R, Dawnay A, Thornalley PJ. Profound mishandling of protein glycation degradation products in uremia and dialysis. J Am Soc Nephrol 2005;16:1471-85.
135. Hartog JW, de Vries AP, Lutgers HL, Meerwaldt R, Huisman RM, van Son WJ et al. Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease. Ann N Y Acad Sci 2005;1043:299-307.
136. Henle Th. AGEs in foods: Do they play a role in uremia? Kidney International 2003;63(Suppl 84):S145-S7.
137. Mendoza MR, Olano A, Villamiel M. Chemical indicators of heat treatment in fortified and special miles. J Agric Food Chem 2005;53:2995-9.
138. Baptista JAB, Carvalho RCB. Indirect determination of Amadori compounds in milk-based products by HPLC/ELSD/UV as an index of protein deterioration. Food Res Intern 2004;37:739-47.
139. Drusch S, Faist V, Erbersdobler HF. Determination of NÂ- carboxymethyllysine in milk products by a modified reversed-phase HPLC method. Food Chemistry 1999;65:547-53.
140. Meissner K, Erbersdobler HF. Maillard reaction in microwave cooking: Comparison of early Maillard products in conventionally and microwave-heated milk. J Sci Food Agric 1996;70:307-10.
141. Dündaröz R, Ulucan H, Aydin HI, Güngör T, Baltaci V, Denli M et al. Analysis of DNA damage using the comet assay in infants fed cow's milk. Biol Neonate 2003;84:135-41.
142. Braly J, Hoggan R. Dangerous grains. New York: Avery-Penguin Putnam Inc.; 2002.
143. Goldberg T, Cai W, Peppa M, Dardaine V, Baliga BS, Uribarri J et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 2004;104:1287-91.
144. Jagerstad M, Skog K. Genotoxicity of heat-processed foods. Mutat Res 2005;574:156-72.
145. Maleki SJ, Hurlburt BK .Structural and functional alterations in major peanut allergens caused by thermal processing. J AOAC Int 2004;87:1475-9.
146. Chung SY, Butts CL, Maleki SJ, Champagne ET. Linking peanut allergenicity to the processes of maturation, curing, and roasting. J Agric Food Chem 2003;51:4273-7.
147. Lunceford N, Gugliucci A. Ilex paraguariensis extracts inhibit AGE formation more efficiently than green tea. Fitoterapia 2005;76:419-27.
148. Bixby M, Spieler L, Menini T, Gugliucci A. Ilex paraguariensis extracts are potent inhibitors of nitrosative stress: a comparative study with green tea and wines using a protein nitration model and mammalian cell cytotoxicity. Life Sci 2005;77:345-58.
149. Kuhlmann MK, Levin NW. Interaction between nutrition and inflammation in hemodialysis patients. Contrib Nephrol 2005;149:200-7.
150. Kalousová M, Zima T, Popov P, Spacek P, Braun M, Soukupová J et al. Advanced glycation end-products in patients with chronic alcohol misuse. Alcohol 2004;39:316-20.
151. Perrocheau L, Rogniaux H, Boivin P, Marion D. Probing heat-stable water-soluble proteins from barley to malt and beer. Proteomics 2005;5:2849-58.
152. Kuhlmann MK, Levin NW. Interaction between nutrition and inflammation in hemodialysis patients. Contrib Nephrol 2005;149:200-7.
153. McCarty MF. The low-AGE content of low fat vegan diets could benefit diabetics - though concurrent taurine supplementation may be needed to minimize endogenous AGE production. Med Hypotheses 2005,64:394-8.
154. Sebeková K, Krajcoviová-Kudlácková M, Schinzel R, Faist V, Klvanová J, Babinská K et al. Plasma levels of advanced glycation end products in healthy, long-term vegetarians and subjects on a western mixed diet. Eur J Nutr 2001;40:275-81.
155. Meyer TE, Kovács SJ, Ehsani AA, Klein S, Holloszy JO, Fontana L. Long-term caloric restriction ameliorates the decline in diastolic function in humans. J Am Coll Cardiol 2006;47:398-402.
156. Iwashige K, Kouda K, Kouda M, Horiuchi K, Takahashi M, Nagano A et al. Calorie restricted diet and urinary pentosidine in patients with rheumatoid arthritis. J Physiol Anthropol Appl Human Sci 2004;23:19-24.
157. Osawa T, Kato Y. Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia. Ann N Y Acad Sci 2005;1043:440-51.
158. Mattsson MP. Will caloric restriction and folate protect against AD and PD? Neurology 2003;60:690-5.
159. Bengmark S. Curcumin: an atoxic antioxidant and natural NF-ÎB, COX-2, LOX and iNOS inhibitor a shield against acute and chronic diseases. JPEN J Parenter Enteral Nutr 2006;30:45-51.
160. McCarty MF. Nutraceutical resources for diabetes prevention - an update. Medical Hypotheses 2005;64:151-8.
161. McCarty MF. Potential utility of natural polyphenols for reversing fat-induced insulin resistance. Med Hypotheses 2005;64:628-35.
162. McCarty MF. The reported clinical utility of taurine of ischemic disorders may reflect a down-regulation of neutrophil activation and adhesion. Med Hypotheses 1999;53:290-9.
163. Laidlaw S, Grosvenor M, Kopple JD. The taurine content of common foodstuffs. JPEN J Parenter Enteral Nutr 1990;14:183-8.
164. Hansen SH. The role of taurine in diabetes and the development of diabetic complications. Diabetes Metab Res Rev 2001;17:330-4.
165. Nandhini ATA, Thirunavakkarasu V, Anuradha CV. Stimulation of glucose utilization and inhibition of protein glycation and AGE products by taurine. Acta Physiol Scand 2004;181:297-303.
166. Nandhini ATA, Thirunavakkarasu V, Anuradha CV. Taurine prevent collagen abnormalities in high fructose-fed rats. Indian J Med Res 2005;122:171-7.
167. Finegold SM, Sutter VL, Mathisen GE. Normal indigenous intestinal flora. In: Hentges DJ, editor. Human intestinal microflora in health and disease. London: Academic Press; 1983. p. 3-31.
168. di Cagno R, de Angelis M, Alfonsi G, de Vincenzi M, Silano M, Vincentini O et al. Pasta made from durum wheat semolina fermented with selected lactobacilli as a tool for a potential decrease of the gluten intolerance. J Agric Food Chem 2005;53:4393-02.
169. Tavan E, Cayuela C, Antoine JM, Cassand P. Antimutagenic activities of various lactic acid bacteria against food mutagens: heterocyclic amines. J Dairy Res 2002;69:335-41.
170. Erbersdobler H, Gunsser I, Weber G. Abbau von Fructoselysine durch die Darmflora. Zentralblatt Vet Med 1970;A17:573-5.
171. Ilkgul O, Bengmark S, Aydede H, Erhan Y, Taneli F, Ulman C Pretreatment with pro- and synbiotics reduces peritonitis-induce lung injury in rats. J Trauma 2007;62:880-5.
172. Ilkgul O, Aydede H, Erhan Y et al. Subcutaneous administration of live lactobacillus prevents sepsis-induced lung organ failure in rats. Br J Int Care 2005;15:52-57.
173. Riordan SM, Skinner N, Nagree A, McCallum H, McIver CJ, Kurtovic J et al. Peripheral blood mononuclear cell expression of Toll-like receptors and relation to cytokine levels in cirrhosis. Hepatology 2003;37:1154-64.
174. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with liver cirrhosis. Hepatology 2004;39:1441-9.
175. Odetti P, Angelini G, Dapino D, Zaccheo D, Garibaldi S, Dagna-Bricarelli F et al. Early glycoxidation damage in brains from Down's syndrome. Biochem Biophys Res Commun 1998;243:849-51.
176. Hudson VM. New insights into the pathogenesis of cystic fibrosis: pivotal role of glutathione system dysfunction and implications for therapy. Treat Respir Med 2004;3:353-63.
177. Foell D, Seeliger S, Vogl T et al Expression of S100A12 (EN-RAGE) in cystic fibrosis. Thorax 2003;58:613-7.
178. Altamura AC, Boin F, Maes M. HPA axis and cytokines dysregulation in schizophrenia: potential implications for the antipsychotic treatment. Eur Neuropsychopharmacol 1999;10:1-4.
179. Muller N, Riedel M, Schwarz MJ. Psychotropic effects of COX-2 inhibitors - a possible new approach for the treatment of psychiatric disorders. Pharmacopsychiatry 2004;37:266-9.
180. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006;27:24-31.
181. Gundersen Y, Opstad PK, Reistad T et al. Seven days' around the clock exhaustive physical exertion combined with energy depletion and sleep deprivation primes circulating leukocytes. Eur J Appl Physiol 2006;97:151-7.
182. Müller N, Schwarz MJ, Defining S, Douhe A, Cerovecki A, Goldstein-Müller B et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006;11:680-4.
183. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000;343:16-22.
184. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG et al. Diet, lifestyle and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001;345: 790-7.
185. Platz EA, Willett WC, Colditz GA, Rimm EB, Spiegelman D, Giovannucci E. Proportion of colon cancer risk that might be preventable in a cohort of middle-aged US men. Cancer Causes Control 2000;11: 579-88.
186. Bengmark S. Bioecological control of inflammation and infection in critical illness. Anaesthesiology Clinics of North America 2006;24:299-323.